Unbiased AI-powered news
5 stories related to this topic, newest first.
qz.comPatients lost 13 percent of body weight on the highest dose after 76 weeks. Liver-fat reduction exceeded placebo by a wide margin.
BenzingaGilead Sciences released Phase 3 IDEAL study data showing Livdelzi achieved statistically significant ALP normalization versus placebo after 52 weeks in patients with inadequately controlled primary biliary cholangitis.
jmir.orgA study published in Cell Stem Cell reports that infusions of macrophages were associated with reduced mortality and fewer liver transplants among people with cirrhosis. The findings come from research led by P. N. Brennan and colleagues.
manilatimes.netGENFIT will present seven posters at the EASL Congress 2026 covering research on acute-on-chronic liver failure and real-world data. The company also noted upcoming meetings on ACLF definitions and governance.
Substrate placeholder — needs reviewA common drinking pattern may raise the risk of advanced liver disease. Fox News Health reported on this and other health topics this week, including bacterial disease prevention and vaccine effects on Alzheimer's. The coverage includes factors for stroke risk and links between s…